Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TLPH 
Talphera Inc. (TLPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: TLPH (3-star) is a STRONG-BUY. BUY since 14 days. Simulated Profits (75.00%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.25
1 Year Target Price $3.25
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 61.25% | Avg. Invested days 31 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.29M USD | Price to earnings Ratio - | 1Y Target Price 3.25 |
Price to earnings Ratio - | 1Y Target Price 3.25 | ||
Volume (30-day avg) 2 | Beta -0.17 | 52 Weeks Range 0.38 - 1.20 | Updated Date 09/15/2025 |
52 Weeks Range 0.38 - 1.20 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -49459.26% |
Management Effectiveness
Return on Assets (TTM) -40.35% | Return on Equity (TTM) -117.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12500295 | Price to Sales(TTM) 714.49 |
Enterprise Value 12500295 | Price to Sales(TTM) 714.49 | ||
Enterprise Value to Revenue 462.97 | Enterprise Value to EBITDA 0.11 | Shares Outstanding 20522700 | Shares Floating 18046186 |
Shares Outstanding 20522700 | Shares Floating 18046186 | ||
Percent Insiders 1.08 | Percent Institutions 13.56 |
Upturn AI SWOT
Talphera Inc.
Company Overview
History and Background
Talphera Inc. was founded in 2005 as a biotechnology company focused on developing innovative therapies for autoimmune diseases. Initially a small research operation, Talphera expanded through strategic partnerships and successful clinical trials.
Core Business Areas
- Pharmaceutical Development: Focuses on researching, developing, and commercializing novel therapies for autoimmune and inflammatory diseases. Includes activities from drug discovery to clinical trials and regulatory approval.
- Diagnostics: Develops and markets diagnostic tests for early detection and monitoring of autoimmune conditions.
- Licensing: Licenses out intellectual property and drug candidates to other pharmaceutical companies for further development and commercialization, generating revenue through royalties and milestone payments.
Leadership and Structure
The company is led by a CEO and a board of directors. The organizational structure includes departments for research and development, clinical operations, marketing, sales, and finance.
Top Products and Market Share
Key Offerings
- Talphera-A: A novel biologic therapy for rheumatoid arthritis. It holds approximately 15% market share in the biologics segment for RA treatment. Competitors include AbbVie's Humira (ABBV) and Amgen's Enbrel (AMGN). Revenue generated is around 1.2 billion USD annually
- AutoDetect Kit: A diagnostic kit for early detection of lupus. Competitors include Quest Diagnostics (DGX) and Labcorp (LH). It has an estimated 10% market share with revenue generated around 250 million USD annually.
Market Dynamics
Industry Overview
The autoimmune disease treatment market is growing due to increasing prevalence of autoimmune disorders and advancements in therapeutic options.
Positioning
Talphera Inc. is a mid-sized player in the autoimmune disease market, focused on developing novel therapies and diagnostics. It competes with larger pharmaceutical companies and specialized biotech firms.
Total Addressable Market (TAM)
The total addressable market for autoimmune disease treatments is estimated at $150 billion. Talphera Inc. is positioned to capture a larger share of this market through its pipeline of innovative products.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Novel therapeutic approach
- Strategic partnerships
- Experienced management team
Weaknesses
- Limited marketing and sales reach compared to larger competitors
- Reliance on a few key products
- High R&D expenses
- Vulnerable to patent expirations
Opportunities
- Expansion into new therapeutic areas
- Acquisition of smaller biotech companies
- Geographic expansion into emerging markets
- Development of personalized medicine approaches
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval delays
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- ABBV
- AMGN
- BMY
- JNJ
Competitive Landscape
Talphera Inc. competes with larger pharmaceutical companies and specialized biotech firms. Talphera has advantages in its innovative therapies. Disadvantages include limited resources for marketing.
Major Acquisitions
BioImmune Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition of BioImmune Solutions to expand its pipeline of autoimmune disease therapies.
Growth Trajectory and Initiatives
Historical Growth: Talphera Inc. has experienced steady growth in revenue and earnings over the past five years, driven by successful product launches and market expansion.
Future Projections: Analysts project continued growth in revenue and earnings over the next five years, driven by the company's pipeline of new products and expansion into new markets.
Recent Initiatives: Recent strategic initiatives include the acquisition of a smaller biotech company and the launch of a new clinical trial for a promising drug candidate.
Summary
Talphera Inc. is a moderately strong company with a promising pipeline in the autoimmune disease market. Their strategic acquisitions and partnerships are working well. They need to be mindful of the larger competitors and patent expirations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Talphera Inc.
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2011-02-11 | CEO & Director Mr. Vincent J. Angotti | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://talphera.com |
Full time employees 13 | Website https://talphera.com | ||
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.